694results about "Haemofiltration" patented technology

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Methods for aspiration to remove thrombus / clot material using a system configured to remove, filter and return clot. These methods allow the removal of clot material using a fluidically-driven aspiration device when attached to an aspiration catheter and proximate to obstructive clot material. A fluidic actuator drives an aspirator, which may be automatically controlled to apply a vacuum in a pattern to enhance clot removal and collection from the body as well as improve blood return using the same closed system. The fluidic actuator may direct the aspirated blood through a filter and deaerator to allow the filtered blood to be returned to the patient.

Components for a medical infusion fluid handling system, such as an APD system, in which one or more lines (such as solution lines), spikes or other connection ports may be automatically capped and / or de-capped. This feature may provide advantages, such as a reduced likelihood of contamination since no human interaction is required to de-cap and connect the one or more lines, the spikes, or the other connection ports. For example, a fluid handling cassette may include one or more caps that cover a corresponding spike and include a raised and / or recessed feature to assist in removal of the one or more caps from the cassette. A solution line cap may include a hole and a recess, a groove or other feature to engage with a spike cap and enable removal of the spike cap.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

The present invention provides a method of removing microplastics from blood or body of a subject, including one or more tissues of the subject, by extracorporeal blood purification, including by plasma exchange, such as double filtration plasma exchange. The present invention also provides a method of treating medical conditions and methods of improving healthy lifespan and lifespan using extracorporeal blood purification, including plasma exchange, such as double filtration plasma exchange, such as by filtering microplastics from blood, and removing microplastics from a tissue or body of a subject, such as a human subject.

A method includes detecting a startup of an apheresis machine; in response to detecting start up, transmitting data to a server; determining, based on the data, whether software of the apheresis machine is current; receiving, in response to the data, a response from the server; and preventing usage of apheresis machine if the response indicates the software is not current. The data transmitted to the server may include one or more of a data log, a firmware version identifier, and an error log. The response may include a lockout signal. The response may include a software update. The software update may include a firmware update. The method may include automatically initiating installation of the software update. The method may include ceasing prevention of usage of the apheresis machine following installation of the software update.

Components for a medical infusion fluid handling system, such as an APD system, in which one or more lines (such as solution lines), spikes or other connection ports may be automatically capped and / or de-capped. This feature may provide advantages, such as a reduced likelihood of contamination since no human interaction is required to de-cap and connect the lines, spikes or other connections. For example, a fluid handling cassette may include one or more caps that cover a corresponding spike and include a raised and / or recessed feature to assist in removal of the cap from the cassette. A solution line cap may include a hole and recess, groove or other feature to engage with a spike cap and enable removal of the cap.

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

A blood reintroduction system can include a canister having a chamber configured to collect blood. A system may include an inlet configured to fluidically connect the chamber to a first tubing in fluid communication with an aspiration catheter. A system may include a first filter within the chamber, wherein the first filter is configured to separate blood from thrombus. A system may include a second filter downstream of the first filter, wherein the second filter is configured to separate blood from thrombus. A system may include a second tubing connected to an outlet of the chamber, wherein the second tubing is configured to reintroduce filtered blood from the chamber to a patient's vasculature.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

The invention belongs to the technical field of medical equipment, and discloses a movable continuous blood purification first-aid device which comprises a movable seat and further comprises a stabilizing mechanism arranged in the inner wall of the bottom end of the movable seat; the blood purification barrel is fixedly connected to the outer wall of the top end of the movable seat, and a cover plate is arranged on the outer wall of the blood purification barrel; the cleaning mechanism is arranged in the inner wall of the blood purification barrel; the mounting mechanism is arranged on the outer wall of the bottom end of the blood purification barrel, and an impurity output pipe is arranged on the inner wall of the mounting mechanism; wherein the stabilizing mechanism comprises a stabilizing plate; through cooperation of the stabilizing plate, the pedal A and other structures, the stabilizing plate can be moved downwards and fixed by treading the pedal A downwards, the stabilizing plate is kept in a state of being in contact with the ground, the overall stability of the device is improved, and then it is guaranteed that in the using process, it is avoided that the device topples over due to external force collision, and the blood purification operation is affected.

Disposable set for an extracorporeal blood treatment apparatus including a blood circuit comprising a filtration unit, a blood withdrawal line including a blood pump tract configured to be engaged by a blood pump, a blood return line, and an infusion line extending between a first end connected to the blood withdrawal line upstream the blood pump tract, and a second end for connection to an infusion substance source: the blood pump tract is interposed between the filtration unit and the first end of the infusion line. The disposable set further comprises a pressure damper arranged towards or at the first end of the infusion line, the pressure damper being configured to prevent, or reduce an amount of, the access negative pressure to extend in the infusion line upstream the pressure damper.

The present document discloses a medical pumping system (20) for moving a fluid through a tube, which may comprise a machine having a motor (24) and a drive mechanism (25), and a pump head configured to be removably coupled to the drive mechanism of the machine. The machine may comprise an inductive sensor (26) and at least one processor (28) connected to the motor and the inductive sensor. The pump head may comprise a metallic element (32) intended to cooperate with the inductive sensor of the machine.

Methods and apparatuses for blood clot aspiration. Described are fluid management components and assemblies for blood clot extraction from a patient's body and for filtering blood and recirculating blood back into the patient's body.

A medical fluid management assembly includes a pneumatic manifold, at least one valve, and a fluid manifold. The pneumatic manifold includes at least one pneumatic passageway that is pneumatically connected to the at least one valve. The fluid manifold includes at least one chamber comprising upper and lower fluid chambers separated by a flexible membrane. The fluid manifold also includes fluid tube sections and fluid pathways that fluidly couple the one or more upper and lower fluid chambers to the at least one valve and at least one of a purified water line, a liquid concentrate line, a to-extracorporeal circuit fresh dialysis fluid line, a drain line, or a from-extracorporeal circuit used dialysis fluid line.

Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

The invention provides a method and a device for secondary filtration and re-removal of cholesterol ester after continuous blood purification and blood fat filtration, and belongs to the technical field of medical blood purification. According to the method and the device, the technology of combining enzymolysis, adsorption and membrane separation is adopted for residual CE in a CBP filtering product. The method comprises the following steps: firstly, decomposing CE into small molecules by using specific enzyme, and weakening the combination of CE and other components; residual impurities are further adsorbed through a high-performance adsorption material; and finally, efficient removal of CE is realized by virtue of a high-precision membrane separation technology, so that the residual quantity is reduced to be below a safety threshold value. Compared with a traditional technology, the problems that the CE-containing filtrate is high in recycling risk and low in resource utilization rate are effectively solved, the purity of a filtered product is remarkably improved, technical support is provided for industrial scenes such as plasma exchange, filtrate feedback, biopharmacy and extracorporeal circulation in the medical field, and the application prospect is wide. The safety and the resource utilization efficiency of the blood purification technology are promoted.

A blood treatment machine includes a patient comfort feedback mechanism configured to be adjusted by a patient to indicate comfort levels of the patient. The machine is configured to adjust one or more treatment parameters based on the patient feedback.

A semipermeable membrane comprises a sulfonated polyarylene ether copolymer and is sterilized with ethylene oxide gas. The sulfonated polyarylene ether copolymer includes a hydrophobic segment repeating unit represented by a formula (1) and a hydrophilic segment repeating unit represented by a formula (2) as copolymerization components.

The present disclosure relates to a fluid filtration device, and methods of making and using the fluid filtration device of the present disclosure. The fluid filtration device includes a frame having a porous member fixed thereto, and the frame is rotatably supported within a housing. The fluid and particles therein are introduced via a non-tangential inlet, and components of the fluid may be filtered through the porous member, producing filtrate (and particles passing through the porous member) and retentate (and particles not passing through the porous member). Some embodiments include a baffle at the entrance. Methods of manufacture (and assembly) and methods of using the fluid filtration devices of the present disclosure are also described.

This invention relates to a filter membrane and its preparation method, particularly to a platelet-rich suspension leukocyte-removing filter membrane and its preparation method. The method uses polyethersulfone (PES) material, which has stable mechanical properties, heat resistance, and chemical properties, as the core material, and polylactic acid (PLA) material, which has good biocompatibility and safety, as the outer material. A coaxial electrospinning process is employed to prepare the PES-PLA filter membrane. Furthermore, a vinylpyrrolidone-acrylamide copolymer is grafted onto the surface of the PES-PLA filter membrane. The resulting platelet-rich suspension leukocyte-removing filter membrane has a narrow pore size distribution, high porosity, and good hydrophilicity, biocompatibility, and antibacterial properties. It can effectively filter out leukocytes from platelet suspensions and reduce the risk of bacterial contamination.

The invention relates to new toxin-binders for hemodialysis. The invention relates to an apoferritin nanoparticle for use as a toxin-binder in hemodialysis. The apoferritin nanoparticle comprises apoferritin subunits that, when combined to the apoferritin nanoparticle, form an inner cavity, and the apoferritin nanoparticle does not contain any nanoparticles in its inner cavity. The invention also relates to a composition, a sorption cartridge and a dialysis system.